Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00624338




Registration number
NCT00624338
Ethics application status
Date submitted
15/02/2008
Date registered
27/02/2008
Date last updated
14/03/2016

Titles & IDs
Public title
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
Scientific title
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Secondary ID [1] 0 0
27646
Universal Trial Number (UTN)
Trial acronym
APRIL-SLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lupus Erythematosus, Systemic 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atacicept 75 mg
Treatment: Drugs - Atacicept 150 mg
Other interventions - Placebo Comparator

Experimental: Atacicept 75 mg -

Experimental: Atacicept 150 mg -

Placebo comparator: Placebo -


Treatment: Drugs: Atacicept 75 mg
75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

Treatment: Drugs: Atacicept 150 mg
150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.

Other interventions: Placebo Comparator
Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Experiencing a New Flare as Defined by British Isles Lupus Assessment Group (BILAG) Score A or B
Timepoint [1] 0 0
From screening up to Week 52
Secondary outcome [1] 0 0
Time to First New Flare as Defined by BILAG Score A or B
Timepoint [1] 0 0
From screening up to Week 52
Secondary outcome [2] 0 0
Percentage of Participants Experiencing a New Flare as Defined by BILAG Score A or B During Initial 24 Weeks
Timepoint [2] 0 0
From screening up to Week 24
Secondary outcome [3] 0 0
Percentage of Participants Within Ordinal Response Categories for British Isles Lupus Assessment Group (BILAG) Flares
Timepoint [3] 0 0
Week 52
Secondary outcome [4] 0 0
Mean Cumulative Corticosteroid Dose
Timepoint [4] 0 0
Randomization up to Week 52

Eligibility
Key inclusion criteria
* Male or female 16 years of age or older
* Disease history of at least six months meeting at least 4 out of the 11 American College of Rheumatology (ACR) criteria for SLE
* Active SLE with at least one British Isles Lupus Assessment Group (BILAG) flare A or B at screening requiring a change in the dose of corticosteroids
* Positive antinuclear antibody (ANA) or anti-double-stranded deoxyribonucleic acid (dsDNA) at screening
* Female subjects must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks prior to Study Day 1, during the trial and 24 weeks after the last dose of study medication
* Other protocol defined inclusion criteria could apply
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Active moderate to severe glomerulonephritis (kidney impairment) as defined in the protocol
* Active central nervous system SLE deemed to be severe/progressive and/or associated with significant cognitive impairment leading to inability to provide informed consent and/or comply with the protocol
* Previous treatment with rituximab, abatacept, or belimumab
* History of demyelinating disease such as multiple sclerosis (MS) or optic neuritis
* Other protocol defined exclusion criteria could apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2012
Sample size
Target
Accrual to date
Final
461
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Cairns
Recruitment hospital [2] 0 0
Research Site - Clayton, Victoria
Recruitment hospital [3] 0 0
Research Site - Sunshine Coast, Queensland
Recruitment hospital [4] 0 0
Research Site - Woodville S.A.
Recruitment postcode(s) [1] 0 0
- Cairns
Recruitment postcode(s) [2] 0 0
- Clayton, Victoria
Recruitment postcode(s) [3] 0 0
- Sunshine Coast, Queensland
Recruitment postcode(s) [4] 0 0
- Woodville S.A.
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Idaho
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Argentina
State/province [11] 0 0
Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Cordoba
Country [13] 0 0
Argentina
State/province [13] 0 0
Quilmes
Country [14] 0 0
Argentina
State/province [14] 0 0
San Juan
Country [15] 0 0
Argentina
State/province [15] 0 0
Tucuman
Country [16] 0 0
Austria
State/province [16] 0 0
Wein
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Sofia
Country [18] 0 0
Croatia
State/province [18] 0 0
Osijek
Country [19] 0 0
Croatia
State/province [19] 0 0
Rijeka
Country [20] 0 0
Croatia
State/province [20] 0 0
Split
Country [21] 0 0
Croatia
State/province [21] 0 0
Zagreb
Country [22] 0 0
Czech Republic
State/province [22] 0 0
Prague
Country [23] 0 0
France
State/province [23] 0 0
Bordeaux Pessac
Country [24] 0 0
France
State/province [24] 0 0
Lille
Country [25] 0 0
France
State/province [25] 0 0
Montpelier Cedex
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
France
State/province [27] 0 0
Strasbourg
Country [28] 0 0
France
State/province [28] 0 0
Toulouse
Country [29] 0 0
Germany
State/province [29] 0 0
Berlin
Country [30] 0 0
Germany
State/province [30] 0 0
Erlangen
Country [31] 0 0
Germany
State/province [31] 0 0
Hanover
Country [32] 0 0
Germany
State/province [32] 0 0
Heidelberg
Country [33] 0 0
Germany
State/province [33] 0 0
Herne
Country [34] 0 0
Germany
State/province [34] 0 0
Munchen
Country [35] 0 0
Germany
State/province [35] 0 0
Munster
Country [36] 0 0
Greece
State/province [36] 0 0
Athens
Country [37] 0 0
Greece
State/province [37] 0 0
Thessaloniki
Country [38] 0 0
India
State/province [38] 0 0
Secunderabad, Andhra Pradesh
Country [39] 0 0
Israel
State/province [39] 0 0
Haifa
Country [40] 0 0
Israel
State/province [40] 0 0
Jerasalem
Country [41] 0 0
Israel
State/province [41] 0 0
Petah-Tikva
Country [42] 0 0
Israel
State/province [42] 0 0
Tel Aviv
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Gyeonggi-do
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Seoul
Country [45] 0 0
Latvia
State/province [45] 0 0
Riga
Country [46] 0 0
Lebanon
State/province [46] 0 0
Beirut
Country [47] 0 0
Lithuania
State/province [47] 0 0
Kaunas
Country [48] 0 0
Lithuania
State/province [48] 0 0
Vilnius
Country [49] 0 0
Malaysia
State/province [49] 0 0
Kuala Lumpur
Country [50] 0 0
Malaysia
State/province [50] 0 0
Perak
Country [51] 0 0
Malaysia
State/province [51] 0 0
Seremban
Country [52] 0 0
Mexico
State/province [52] 0 0
Guadalajara Jalisco
Country [53] 0 0
Mexico
State/province [53] 0 0
Tijuana, BC
Country [54] 0 0
Netherlands
State/province [54] 0 0
Amsterdam
Country [55] 0 0
Netherlands
State/province [55] 0 0
Leiden
Country [56] 0 0
Netherlands
State/province [56] 0 0
Maastricht
Country [57] 0 0
Philippines
State/province [57] 0 0
Pampanga
Country [58] 0 0
Philippines
State/province [58] 0 0
Davao
Country [59] 0 0
Philippines
State/province [59] 0 0
Iloilo
Country [60] 0 0
Philippines
State/province [60] 0 0
Las Pinas
Country [61] 0 0
Philippines
State/province [61] 0 0
Manila
Country [62] 0 0
Poland
State/province [62] 0 0
Bialystok
Country [63] 0 0
Poland
State/province [63] 0 0
Gdansk
Country [64] 0 0
Poland
State/province [64] 0 0
Krakow
Country [65] 0 0
Poland
State/province [65] 0 0
Lublin
Country [66] 0 0
Poland
State/province [66] 0 0
Szczecin
Country [67] 0 0
Poland
State/province [67] 0 0
Torun
Country [68] 0 0
Poland
State/province [68] 0 0
Warsawa
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Kemerovo
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Petrozavodsk
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Ryazan
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Saratov
Country [73] 0 0
Russian Federation
State/province [73] 0 0
St Petersburg
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Tula
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Yaroslavl
Country [76] 0 0
Serbia
State/province [76] 0 0
Belgrade
Country [77] 0 0
Serbia
State/province [77] 0 0
Niska Banja
Country [78] 0 0
Serbia
State/province [78] 0 0
Novi Beograd
Country [79] 0 0
South Africa
State/province [79] 0 0
Cape Town
Country [80] 0 0
South Africa
State/province [80] 0 0
Durban
Country [81] 0 0
South Africa
State/province [81] 0 0
Panorama, Western Cape
Country [82] 0 0
South Africa
State/province [82] 0 0
Parlow, Western Cape
Country [83] 0 0
South Africa
State/province [83] 0 0
Pinelands
Country [84] 0 0
South Africa
State/province [84] 0 0
Stellenbosch, Western Cape
Country [85] 0 0
Spain
State/province [85] 0 0
Barcelona
Country [86] 0 0
Spain
State/province [86] 0 0
Madrid
Country [87] 0 0
Spain
State/province [87] 0 0
Malaga
Country [88] 0 0
Spain
State/province [88] 0 0
Santiago de Compostela
Country [89] 0 0
Switzerland
State/province [89] 0 0
St. Gallen
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taichung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taoyuan
Country [93] 0 0
Ukraine
State/province [93] 0 0
Donetsk
Country [94] 0 0
Ukraine
State/province [94] 0 0
Kharkiv
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kyiv
Country [96] 0 0
Ukraine
State/province [96] 0 0
Lviv
Country [97] 0 0
Ukraine
State/province [97] 0 0
Ternopil
Country [98] 0 0
Ukraine
State/province [98] 0 0
Vinnytsya
Country [99] 0 0
Ukraine
State/province [99] 0 0
Zhytomyr
Country [100] 0 0
United Kingdom
State/province [100] 0 0
London
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
EMD Serono
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck KGaA, Darmstadt, Germany
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is to evaluate the efficacy and safety of atacicept compared to placebo in preventing new flares in subjects with systemic lupus erythematosus (SLE) and to confirm the optimal dose of atacicept for treatment of subjects with SLE and gain information on the effect of atacicept on markers specific to its mechanism of action (MoA) and their correlation to disease activity/progression. Study medication will be administered through subcutaneous (under the skin) injections, beginning with twice weekly injections for the first 4 weeks, followed by once weekly doses for 48 weeks. Following the last treatment, a safety follow-up period of 24 weeks will be conducted.
Trial website
https://clinicaltrials.gov/study/NCT00624338
Trial related presentations / publications
Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006-15. doi: 10.1136/annrheumdis-2013-205067. Epub 2014 Jun 20. Erratum In: Ann Rheum Dis. 2016 May;75(5):946. doi: 10.1136/annrheumdis-2013-205067corr1.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Responsible
Address 0 0
Merck KGaA, Darmstadt, Germany
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00624338